8月8日，沪深两融数据显示，祥生医疗获融资买入额0.14亿元，居两市第1030位，当日融资偿还额0.09 亿元，净买入474.35万元。 最近三个交易日，6日-8日，祥生医疗分别获融资买入0.06亿元、0.09亿元、0.14亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...

8月4日，祥生医疗今日收盘33.86元，上涨2.20%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到27.80倍，创99天以来新低，总市值37.97亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13祥生医疗27.8027.022.6037.97亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16.4615.511.0559.74亿6奥美医疗16.5616.231.7059.84亿7康德莱17.8617.871.4838.48亿8九强生物 17.9416.682.2088.83亿9维力医疗18.0819.322.2742.38亿10奥泰生物18.1519.131.4757.88亿11鱼跃医疗 19.9219.542.69352.87亿12安图生物20.2719.352.60231.08亿 无锡祥生医疗科技股份 ...

Policy Developments - The National Health Commission issued a work plan for the integration of medical and elderly care services, promoting the establishment of national demonstration counties and institutions [2] - The criteria for creating demonstration institutions include operating for over 5 years, a bed occupancy rate of at least 65% in the last 2 years, and over 65% of residents being elderly individuals with disabilities or dementia [2] - The plan emphasizes comprehensive health assessments for the elderly, early intervention for age-related diseases, and the use of traditional Chinese medicine and information technology to enhance service quality [2] Drug and Device Approvals - Humanwell Healthcare announced that its subsidiary received a drug registration certificate for the transdermal patch for treating mild to moderate Alzheimer's disease, with a total R&D investment of approximately RMB 19 million [4] - Kehua Bio received medical device registration certificates for two nucleic acid testing kits, valid until July 16, 2030 [5] Financial Reports - Wohua Pharmaceutical reported a 303.16% year-on-year increase in net profit for the first half of the year, with revenue of RMB 425 million, a 7.64% increase [7] Capital Market Activities - Xiangsheng Medical signed an agreement with the Gates Foundation for the joint development and promotion of innovative obstetric and breast ultrasound screening devices, receiving project funding of USD 2.1 million [9] - Sanofi announced a deal to acquire Vicebio for up to USD 1.6 billion, including an upfront payment of USD 1.15 billion and milestone payments of USD 450 million [11] Industry Developments - The National Medical Insurance Administration reported that from January to June 2025, there were 200 million instances of personal account pooling in employee medical insurance, amounting to RMB 26.177 billion [13]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-018 无锡祥生医疗科技股份有限公司 自愿披露关于与盖茨基金会签署联合开发 基本情况：盖茨基金会（前身 BILL & MELINDA GATES FOUNDATION 即 比尔及梅琳达·盖茨基金会）成立于 2000 年，总部设在美国西雅图。其秉承所有 生命价值平等的信念，致力于将人类的创新才能应用于减少健康和发展领域的不 平等现象。基金会资助新想法，以对抗贫困、疾病以及医疗卫生资源、教育和经 济发展机会短缺等问题，开发并且鼓励新型伙伴关系，确保共有的资源能为最广 泛的人群带来最大的益处。基金会愿景是一个人人都有机会过上健康而富有成效 生活的世界。 二、协议的主要内容 根据协议，盖茨基金会将向公司提供合计 210 万美元的项目资助，以支持公 司开发并推广创新型产科及乳腺超声筛查设备。盖茨基金会将根据项目研发目标 /里程碑的达成情况，按约定的付款时间表分阶段支付项目资金。 该项目产品旨在开发创新型超声解决方案。通过在超声设备上集成智能化的 产前辅助筛查和乳腺病变筛查功能，利用智能化分析盲扫获取的超声视频，实现 智能识别产前及围产期妇女的关键高危妊娠风 ...

Group 1 - The core viewpoint of the article highlights that Wuxi Xiangsheng Medical Technology Co., Ltd. has successfully obtained the EU Medical Devices Regulation (MDR) certification for its entire range of digital color ultrasound diagnostic products, marking a significant achievement in aligning with international safety and quality standards [1][2] - The MDR certification serves as a "hard currency" for entering the EU market and provides strong international credibility for the company's expansion into potential markets in Asia-Pacific, the Middle East, and Latin America [1] - Xiangsheng Medical has established a comprehensive technological capability in ultrasound imaging, covering various aspects from core components to clinical applications, thereby creating differentiated advantages in portability, specialization, and intelligence [1][2] Group 2 - The company's products are already utilized in over 30% of tertiary hospitals in China and have been exported to more than 100 countries and regions globally, establishing solid strategic partnerships with renowned international medical device companies [2] - In the field of ultrasound AI diagnostics, Xiangsheng Medical has developed an intelligent standard framework that encompasses device research and development, image acquisition, and diagnostic decision-making, with its breast ultrasound analysis software receiving medical device registration approval in 2022 [2] - The company aims to enhance its global market penetration with the MDR certification as a new starting point, focusing on providing smarter, more precise, and more accessible ultrasound diagnostic services worldwide, thereby strengthening the "China Intelligent Manufacturing" brand in the high-end medical device sector [2]

Core Viewpoint - Xiangsheng Medical (688358) announced a cash dividend distribution of 10 CNY per 10 shares, totaling 111,874,753 CNY, which represents 79.62% of the company's net profit attributable to shareholders for the year [1][2][4] Trading Information Summary - On July 8, 2025, Xiangsheng Medical's stock closed at 29.9 CNY, with a slight decline of 0.07%. The turnover rate was 0.93%, with a trading volume of 10,400 shares and a total transaction value of 31,227,400 CNY [1] - The fund flow on the same day showed a net outflow of 480,670 CNY from main funds, accounting for 15.39% of the total transaction value, while retail funds had a net inflow of 598,990 CNY, representing 19.18% of the total [1][4] Company Announcement Summary - Xiangsheng Medical's 2024 annual profit distribution plan includes a cash dividend of 10 CNY per 10 shares (before tax), with the base for distribution being 111,874,753 shares after deducting 249,784 shares held in the repurchase account [1][2] - The dividend distribution will not involve capital reserve conversion into share capital or the issuance of bonus shares. The record date for the dividend is July 14, 2025, and the ex-dividend date and payment date are both set for July 15, 2025 [1][2]

上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 差异化分红事项之专项法律意见书 致: 无锡祥生医疗科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受无锡祥生医疗科技股份有限公司(以下 简称"祥生医疗"或"公司")的委托, 指派本所孙文律师、李昱程律师(以下合称"本所律 师")根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券 法》(以下简称"《证券法》")、《上海证券交易所上市公司自律监管指引第 7 号——回购 股份》(以下简称"《自律监管指引》")、《上海证券交易所上市公司自律监管指南第 2 号 ——业务办理》等法律、法规及规范性文件(以下简称"法律、法规及规范性文件", 该等 法律、法规及规范性文件不包括香港特别行政区、澳门特别行政区和台湾地区的法律法规) 以及《无锡祥生医疗科技股份有限公司章程》(以下简称"《公司章程》")的规定, 就祥生 医疗 2024 年度利润分配所涉及的差异化分红事项(以下简称"本次差异化分红")相关事项 出具法律意见。 为出具本法律意见书, 本所律师已经严格履行法定职责, 遵循了勤勉尽责和诚实信用 原则, 对祥生医疗本次差异化分红所涉 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-017 无锡祥生医疗科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：是 ? 每股分配比例 每股现金红利1元 ? 相关日期 股权登记日 除权（息）日 现金红利发放日 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（无 锡祥生医疗科技股份有限公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 及其他规范性文件以及《公司章程》的有关规定，公司回购的股份不享有股东大 会表决权、利润分配、公积金转增股本、认购新股和配股等权利。 （1）差异化分红送转方案 根 ...

上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 差异化分红事项之专项法律意见书 致: 无锡祥生医疗科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受无锡祥生医疗科技股份有限公司(以下 简称"祥生医疗"或"公司")的委托, 指派本所孙文律师、李昱程律师(以下合称"本所律 师")根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券 法》(以下简称"《证券法》")、《上海证券交易所上市公司自律监管指引第 7 号——回购 股份》(以下简称"《自律监管指引》")、《上海证券交易所上市公司自律监管指南第 2 号 ——业务办理》等法律、法规及规范性文件(以下简称"法律、法规及规范性文件", 该等 法律、法规及规范性文件不包括香港特别行政区、澳门特别行政区和台湾地区的法律法规) 以及《无锡祥生医疗科技股份有限公司章程》(以下简称"《公司章程》")的规定, 就祥生 医疗 2024 年度利润分配所涉及的差异化分红事项(以下简称"本次差异化分红")相关事项 出具法律意见。 为出具本法律意见书, 本所律师已经严格履行法定职责, 遵循了勤勉尽责和诚实信用 原则, 对祥生医疗本次差异化分红所涉 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-017 无锡祥生医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/14 | 2025/7/15 | 2025/7/15 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（无 锡祥生医疗科技股份有限公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 是否涉及差异化分红送转：是 ...